Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
5.19
+0.07 (1.37%)
At close: Apr 29, 2026, 4:00 PM EDT
5.29
+0.10 (1.93%)
After-hours: Apr 29, 2026, 5:33 PM EDT
Neuphoria Therapeutics Revenue
Neuphoria Therapeutics had revenue of $14.99M in the twelve months ending December 31, 2025, up 2,161.41% year-over-year. In the fiscal year ending June 30, 2025, Neuphoria Therapeutics had annual revenue of $15.65M.
Revenue (ttm)
$14.99M
Revenue Growth
+2,161.41%
P/S Ratio
1.87
Revenue / Employee
$1,873,342
Employees
8
Market Cap
27.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.65M | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 4.17M | 3.48M | 499.60% |
| Jun 30, 2021 | 695.81K | -1.37M | -66.32% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apollomics | 8.99M |
| Kyntra Bio | 6.44M |
| Longeveron | 1.20M |
| ABVC BioPharma | 797.92K |
| Outlook Therapeutics | 205.70K |
| Lisata Therapeutics | 170.00K |
NEUP News
- 5 months ago - Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees - GlobeNewsWire
- 5 months ago - Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium - GlobeNewsWire
- 5 months ago - Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - GlobeNewsWire
- 5 months ago - Neuphoria Therapeutics Inc. Sends Letter to Stockholders - GlobeNewsWire
- 6 months ago - Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value - GlobeNewsWire
- 6 months ago - Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process - GlobeNewsWire
- 6 months ago - PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 months ago - Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire